Ciprofloxacin intratympanic - Otonomy

Drug Profile

Ciprofloxacin intratympanic - Otonomy

Alternative Names: AuriPro™; Ciprofloxacin otic suspension - Otonomy; OTIPRIO; OTO-201

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator Otonomy
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA topoisomerase IV inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis media
  • Phase III Otitis externa

Most Recent Events

  • 04 May 2017 Otonomy plans to complete an end-of-phase II meeting with US FDA for ciprofloxacin intratympanic in Acute otitis media with tympanostomy tubes
  • 04 May 2017 Otonomy files sNDA for Otitis externa in USA
  • 02 Mar 2017 Otonomy has patent protection for ciprofloxacin in USA (Otonomy Form 10-K, March 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top